生物晶制药公司在小股名中名列前茅,预计2025年将赚取560-575亿美元的收入。 BioCryst Pharmaceuticals tops small-cap stock list, expected to earn $560-$575M in 2025.

Apogee Therapeutics 是一家专注于免疫和炎症疾病的小型生物技术公司，在最值得购买的小盘股中排名第 9，拥有有前景的药物试验和 7.54 亿美元的现金。 Apogee Therapeutics, a small biotech company focusing on immunological and inflammatory diseases, ranks 9th among top small-cap stocks to buy, with promising drug trials and $754 million in cash. Argan公司排名第八位,拥有强劲的资产负债表和电力服务部门75%的收入增长,最近股息增加了25%。 Argan, Inc., ranked 8th, boasts a strong balance sheet and 75% revenue growth in its power services segment, with a recent 25% dividend increase. Agios制药公司是另一家生物技术公司,在治疗血液疾病方面增长强劲,有15亿美元的现金,但AI库存可提供更快的回报。 Agios Pharmaceuticals, another biotech firm, sees strong growth in treating blood diseases, with $1.5 billion in cash, but AI stocks may offer faster returns. 生物晶制药公司名列第一,2025年预期收入为560-575亿美元,CAGR目标收入为20%,尽管AI股票可以提供更快的收益。 BioCryst Pharmaceuticals ranks 1st, with $560-$575 million in expected 2025 revenue and a 20% revenue CAGR target, though AI stocks could provide quicker gains.